Tusk Therapeutics Overview
- Founded
-
2015
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$764M
Tusk Therapeutics General Information
Description
Developer of an innate immune system designed to harness the power of the immune system for the treatment of cancer. The company's system is developing novel immune modulating therapeutics based on an in-depth understanding of the innate immune system with a special focus on Natural Killer (NK) cell biology, enabling cancer patients to get full recovery.
Contact Information
Website
www.tusktherapeutics.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Office
- Stevenage Bioscience Catalyst
- Gunnels Wood Road, Stevenage
- Hertfordshire SG1 2FX
- England, United Kingdom
Tusk Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 27-Sep-2018 | $764M | 00000 | Completed | Pre-Clinical Trials | |
| 3. Grant | 14-Nov-2017 | 00.000 | Completed | Pre-Clinical Trials | ||
| 2. Early Stage VC | Completed | Startup | ||||
| 1. Accelerator/Incubator | Completed | Startup |
Tusk Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of an innate immune system designed to harness the power of the immune system for the treatment of cancer. The
Biotechnology
Hertfordshire, United Kingdom
0000
0000-00-00
000000&0
000000
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo con
0000 000000000
Vienna, Austria
00
As of 0000
000.00
0000000000 0
000000
or incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation u
0000000000000
Cambridge, MA
0
As of 0000
0000
0000-00-00
0000000000 0
Add Comparison
Tusk Therapeutics Competitors (39)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| APEIRON Biologics | Venture Capital-Backed | Vienna, Austria | 00 | 000.00 | 0000000000 0 | |
| 0000000 | Venture Capital-Backed | Cambridge, MA | 0 | 0000000000 0 | ||
| 000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| 0000 000000000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 00000000 | 00000 |
| 0000 000000 | Formerly VC-backed | Santa Monica, CA | 000 | 00000 | 000000&0 | 00000 |
Tusk Therapeutics Patents
Tusk Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2019233575-A1 | Anti-cd25 for tumour specific cell depletion | Pending | 13-Mar-2018 | 00000000000 | |
| AU-2019233576-A1 | Anti-cd25 for tumour specific cell depletion | Pending | 13-Mar-2018 | 00000000000 | |
| US-10745485-B2 | Anti-cd25 antibody agents | Active | 13-Mar-2018 | 00000000000 | 00 |
| US-20210040221-A1 | Anti-cd25 for tumour specific cell depletion | Pending | 13-Mar-2018 | 00000000000 | |
| US-20190284287-A1 | Anti-cd25 antibody agents | Granted | 13-Mar-2018 | C07K16/2818 |
Tusk Therapeutics Executive Team (5)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Pascal Merchiers Ph.D | Vice President of Research & Development | ||
| Dominic Smethurst | Chief Medical Officer |
Tusk Therapeutics Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Eric Rowinsky | Tusk Therapeutics | Board Member | 000 0000 |
Tusk Therapeutics Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Droia Oncology Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Innovate UK | Government | 000 0000 | 000000 0 | ||
| Stevenage Bioscience Catalyst | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |